Replimune · RP1 · Apr – Jun 2026
What happened inside Replimune after the second letter?
Job cuts and a smaller manufacturing operation, no in-house commercial staff by the 10-K, and an amended class action. Then, in May, a path forward with the FDA.
EphemerisX Research · Published · 3 source documents · 1 min read
Short answer
The company's April 8-K announced job cuts, including at its U.S. manufacturing operation. By the June 10-K it had no in-house commercial staff, and the class action filed after the first letter had been amended to address the second. The 10-K also reports that in May the company and the FDA aligned on a path forward.
What the evidence shows
April 2026: As we previously communicated, without timely accelerated approval, the development of RP1 will not be viable
8-K · Apr 13, 2026, and at this point we have no choice but to eliminate jobs, including substantially scaling back our U.S. based manufacturing operations
8-K · Apr 13, 2026.
The June 2026 10-K: Following our reduction in force after receiving the second CRL, we no longer have in-house sales, marketing or commercialization staff and will need to rebuild these capabilities
10-K · Jun 29, 2026.
On litigation, the 10-K says that On July 24, 2025, a class action complaint alleging violations of the federal securities laws was filed
10-K · Jun 29, 2026, and that after the second CRL the Lead Plaintiff filed a second amended complaint in the class action that addresses the second CRL
10-K · Jun 29, 2026. The Company and the other defendants deny any wrongdoing
10-K · Jun 29, 2026.
Then: following collaborative communications with the FDA, the Company and the FDA aligned on a path forward for resubmission and reconsideration of the BLA
10-K · Jun 29, 2026. By August, the approval 8-K describes Replimune as a commercial stage biotechnology company
8-K · Aug 7, 2026.
Follow the thread
- What happened to the confirmatory trial Replimune said would not be viable?“Will not be viable,” then job cuts
- How did RP1 go from a second FDA letter to accelerated approval in four months?May 29: “aligned on a path forward”
This investigation connects to
- What happens after a second FDA Complete Response Letter?Cross-investigation · Divergent outcome · with Aldeyra Therapeutics, CorMedix, Outlook Therapeutics, Verrica Pharmaceuticals
- How did two programs move forward after repeat FDA letters without running a new trial?Cross-investigation · Comparable evidence · with Outlook Therapeutics
- What is a Class 1 or Class 2 resubmission, and how did each play out in these records?Cross-investigation · Regulatory pathway · with Aldeyra Therapeutics, CorMedix, Outlook Therapeutics
The documents, by date
The passages quoted
Replimune Form 8-K, filed April 13, 2026
As we previously communicated, without timely accelerated approval, the development of RP1 will not be viable. We are devastated for our committed employees who have worked tirelessly for patients but at this point we have no choice but to eliminate jobs, including substantially scaling back our U.S. based manufacturing operations.Open at the source →
Replimune Form 10-K, filed June 29, 2026
We announced on May 29, 2026, that following collaborative communications with the FDA, the Company and the FDA aligned on a path forward for resubmission and reconsideration of the BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma.Open at the source →
Replimune Form 10-K, filed June 29, 2026
Following the second CRL issued by the FDA on April 10, 2026 for the Company's RP1 BLA for the treatment of advanced melanoma, the Lead Plaintiff filed a second amended complaint in the class action that addresses the second CRL.Open at the source →
Replimune Form 10-K, filed June 29, 2026
On July 24, 2025, a class action complaint alleging violations of the federal securities laws was filed against the Company and its directors and certain officers in the United States District Court for the District of MassachusettsOpen at the source →
Replimune Form 10-K, filed June 29, 2026
The Company and the other defendants deny any wrongdoing and continue to vigorously defend this action.Open at the source →
Replimune Form 10-K, filed June 29, 2026
Following our reduction in force after receiving the second CRL, we no longer have in-house sales, marketing or commercialization staff and will need to rebuild these capabilities to commercialize any of our product candidates, if approved.Open at the source →
Replimune Form 8-K, filed August 7, 2026
a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapiesOpen at the source →